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1. Introduction
In the time of transition from premenopausal state to postmenopausal state the capacity of
ovary producing sex hormones including estrogens, progesterone and testosterone cuts down
[1]. Due to the menopause the level of serum oestrogen dramatically decreases, which increases
the production of bone-resorbing cytokines and osteoblasts and then increases the number and
activity of osteoclast, thereby increasing the bone loss [2]. Hormonal replacement therapy
(HRT) is able to prevent bone loss for sex hormones-deficient menopausal women and
consequently is of clinical importance for the treatment of osteoporosis. [1-3] In Europe and
USA the osteoporosis prevention of 25-50% of the post-menopausal women rely on HRT [2,5,
6]. In past years, however, the large international studies, such as the randomized Woman
Health Initiative, the observational Million Women Study and the Women’s International
Study of long Duration, discussed both of the adverse and beneficial effects of post-menpausal
HRT [7]. In respect of the adverse effects, the discussion was focused on HRT induced risk of
breast cancer [8-11], venous thromboembolism [12], stroke and myocardial infarction [13], as
well as coronary heart diseases [14]. To limit these adverse effects a series of regimens of HRT,
such as continuous combination of oestrogen and progestogen or continuous oestrogen and
interruptted progestogen [15], and with dehydroepiandrosterone as a new strategic tool [16],
were developed. In general these regimens confer no positive result, and thus new strategies
are still needed.
Osteoporosis relates to both the decrease of the formation of osteoblast-modulated bone and
the increase of the resorption osteoclast-modulated bone. Estrogen directly up-modulates the
activity and the proliferation of osteoblasts, and/or regulats the gene expression in osteoblasts
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and osteoclasts [17-20]. Bone resorption is regulated by the adhesion of osteoclasts to the
surface of the bone, which is mediated by the receptor αvβ3 integrin and its recognition to RGD
(Arg-Gly-Asp) containing protein of osteoclasts [21]. These suggest that the activity and
proliferation of osteoblasts and the adhesiveness of osteoclasts can be simultaneously up-
regulated with estrogen and down-regulated with RGD peptide, respectively. On the other
hand, it was explored that the covalent modifications of hydrocortisone and estrone with
kyotorphin (a dipeptide, Tyr-Arg) may increase the analgesic activities of hydrocortisone and
estrone [22], as well as the covalent modifications of hydrocortisone and prednisolone with
urotoxins (Gly-Asp-Gly, His-Gly-Gly, His-Gly-Lys and His-Gly-Lys-NHNH2) may increase
the immunosuppressive activities of hydrocortisone and prednisolone [23]. Similarly, the anti-
osteoporosis activities of estrone and estradiol were enhanced by growth hormone releasing
peptides (GHRPs: Tyr-Gly-Gly-Phe-Met-NH2, Tyr-Gly-Gly-Phe-Met, Tyr-Gly-Gly-Phe-Leu-
NH2, Tyr-Gly-Gly-Phe-Leu, Tyr-Gly-Gly-Phe-Gly-NH2 and Tyr-Gly-Gly-Phe-Gly) [24-26]. In
this context a strategy to enhance anti-osteoporosis potency and reduce adverse effects of HRT
was practiced by covalent modifications of sex hormone with RGD-peptides.
2. Covalent modifications of estrogen with RGD-peptides and ip treated
ovariectomy mice
Estrogens including estrone, estradiol, estriol, conjugated estrogen and tibolone have been
widely used in HRT. Upon the promotion of the enzyme both estrone and estradiol can be
converted to ertriol. Conjugated estrogen is an oral estrogen isolated from the urine of gravid
horse and contains estrone monosodium sulfate (50.0% - 63.0%), equilin monosodium sulfate
(22.5% - 32.5%), a few of 17α-estradiol monosodium sulfate and equilenin monosodium sulfate.
Tibolone is an analog of norethynodrel. Of these estrogens, estrone and estradiol are the
common parents and estradiol is the major agents of HRT. Thus estradiol and estrone were
covalently modified by RGD-peptides (1-9, Figure 1) and evaluated with ip treated ovariec‐
tomy mice [27].
Figure 1. Structures of conjugates of estradiol-RGD-tetrapeptides. In 1, 4,7 AA = Ser, in 2, 5, 8 AA = Val, in 3, 6, 9 AA =
Phe.
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2.1. Covalent modification of estradiol with RGD-tetrapeptides decreasing bone turnover
Using succinyl group as the linker the covalent modifications of the 17β-hydroxy of estradiol
with RGD-tetrapeptides provided conjugates 1-3, and using carbonylmethyl group as the
linker the covalent modifications of the 3-hydroxy of estradiol or estrone with RGD-tetrapep‐
tides provided conjugates 4-9 (Figure 1). The changes of the levels of the serum calcium and
serum alkaline phosphatase (ALP) of the mice receiving ip injection of 1-6 for 4 weeks are
shown in Figure 2. After the treatments of conjugates 1-6 the levels of serum calcium and serum
ALP of the treated mice are significantly lower than that of ovariotomy and estradiol treated
mice. This means that the ip injection efficacy of conjugates 1-6 in decreasing the serum calcium
and serum ALP is significantly higher than that of estradiol. Due to serum ALP been the
biomarker of bone turnover low serum ALP means conjugates 1-6 benefits the inhibition of
bone turnover.
Figure 2. Serum calcium and serum ALP of 1-6 treated mice. Dose = 110.3 μmol/kg, n=12, a) Compared to ovariotomy
P<0.05; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy and estradiol P<0.01. The statistical analysis
of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
2.2. Covalent modification of estradiol with RGD-tetrapeptides inhibiting bone loss
The effects of ip injection of 1-6 for 4 weeks on the bone loss of the mice are shown in Figure
3. The level of bone loss is represented with the weight of dry femur and the weight of femur
ash. The data indicate that the weight of dry femur and the weight of femur ash of 1-6 treated
mice are significantly higher than those of ovariotomy and estradiol treated mice. This means
that ip injection efficacy of 1-6 in inhibiting the bone loss is significantly higher than that of
estradiol, and the covalent modification of estradiol with RGD-tetrapeptides benefits the
inhibition of bone loss.
2.3. Covalent modification of estrone with RGD-tetrapeptides inhibiting bone turnover
Using carbonylmethyl group as the linker the covalent modifications of the 3-hydroxy of
estrone with RGD-tetrapeptides provided conjugates 7-9 (Figure 4). The effects of ip injection
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of 7-9 for 4 weeks on serum calcium and serum ALP of the mice are shown in Figure 4. The
serum calcium and serum ALP of 7-9 treated mice are significantly lower than that of ovar‐
iotomy and estrone treated mice. This means that the ip injection efficacy of conjugates 7-9 in
decreasing the serum calcium and serum ALP is significantly higher than that of estrone. Due
to serum ALP reflecting the level of bone turnover and low serum ALP corresponding with
low bone turnover, 7-9 benefits the inhibition of bone turnover.
Figure 4. Serum calcium and ALP of 7-9 treated mice. Dose = 110.3 μmol/kg, n=12, a) Compared to ovariotomy
P<0.05; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy and estrone P<0.01. The statistical analysis of
the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
2.4. Covalent modification of estrone with RGD-tetrapeptides preventing bone loss
The effect of ip injection of 7-9 for 4 weeks on the bone loss of the mice is shown in Figure 5.
The weight of dry femur and the weight of femur ash of 7-9 treated mice are significantly higher
than that of ovariotomy and estrone treated mice. Due to the weight of dry femur and the
weight of femur ash reflecting the level of bone loss of osteoporosis mice this comparison
means that ip injection efficacy of 7-9 in inhibiting bone loss is significantly higher than that
of estrone and the covalent modification enhances the inhibition of estrone in bone loss.
Figure 3. Weight of dry femur and femur ash of 1-6 treated mice. Dose =110.3 μmol/kg, n=12; a) Compared to ovar‐
iotomy P<0.01; b) Compared to ovariotomy and estradiol P<0.01; c) Compared to ovariotomy and estradiol P<0.05; d)
Compared to ovariotomy P<0.01, to estradiol P<0.05. The statistical analysis of the data was carried out by use of an
ANOVA test and p<0.05 was considered significant.
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Figure 5. Weight of dry femur and femur ash of conjugates 7-9 treated mice. Dose =110.3 μmol/kg, n=12; a) Com‐
pared to ovariotomy P<0.01; b) Compared to ovariotomy P<0.05; c) Compared to ovariotomy P<0.01, to estrone
P<0.05. The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered signifi‐
cant.
2.5. Covalent modification of estrogen with RGD-tetrapeptides inducing no endometrial
cell hyperplasia
The effects of ip injection of 1-9 for 4 weeks on endometrial cell hyperplasia of the mice were
also observed. The weight of the uteri of ovariotomy, estradiol and estrone treated mice is
significantly higher than that of 1-9 treated mice. Due to the weight of the uteri reflecting the
level of endometrial cell hyperplasia of treated mice this comparison means that ip injection
efficacy of 1-9 in inducing endometrial cell hyperplasia is significantly lower than that of
estradiol and estrone and the covalent modification induces no observable endometrial cell
hyperplasia.
2.6. Summary of covalent modification of estrogen with RGD-tetrapeptides
With RGD-tetrapeptides modifying one hydroxyl group of estradiol and estrone resulted in 9
conjugates. On ovariotomy mouse model and at 110.3 μmol/kg of ip dose their anti-osteopo‐
rosis activities were significantly higher than that of estradiol and estrone themselves. In
contrast to estradiol and estrone themselves, the anti-osteoporosis therapy of these conjugates
induced no endometrial cell hyperplasia. It is commonly accepted that osteoporosis relates to
both the decrease in bone formation modulated by osteoblasts and the increase in bone
resorption modulated by osteoclasts. In HRT, estradiol and estrone are used to treat the
decrease in skeletal muscle and bone by the direct modulation of osteoblastic activity and
proliferation or by the regulation of gene expression in osteoblasts and osteoclasts. Bone
resorption is regulated by the binding of osteoclasts to the bone surface and, therefore, depends
upon osteoclast adhesiveness. This bone adhesion process is mediated by RGD-tetrapeptides
binding integrin receptor on cell surface. This action of RGD-tetrapeptides should be respon‐
sible for both the increased anti-osteoporosis activity and the decreased endometrial cell
hyperplasia of the conjugates. Due to ovariotomy mouse model simulates the bone loss
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condition of postmenopausal women these RGD-tetrapeptides modified estradiol and estrone
should be promising candidates for HRT use.
3. Covalent modification of estrogen with RGD-octapeptides and orally
treated ovariectomy mice
It was explored that the modification of RGD-tetrapeptides with oligopeptides usually
increased their bioactivities [28, 29], suggesting the modification of RGD-tetrapeptides with
RGD-tetrapeptides may result in increase of the activity of down-regulating proliferation of
osteoblasts and the adhesiveness of osteoclasts. In this context estradiol and estrone were
modified with RGD-octapeptides (10-21, Figure 6) to evaluate the oral activity on ovariectomy
mice [30, 31].
Figure 6. Structures of conjugates of RGD-octapeptides and estradiol. In 10, 13, 16, 19 AA = Ser, in 11, 14, 17, 20 AA
= Val, in 12, 15, 18, 21 AA = Phe.
3.1. Covalent modification of estradiol with RGD-octapeptides inhibiting bone turnover
Using succinyl group as the linker the 17β-hydroxy of estradiol was modified with RGD-
octapeptides and provided 10-12, using carbonylmethyl group as the linker the 3-hydroxy of
estradiol was modified with RGD-octapeptides and provided 13-15 (Figure 6). The effect of
oral administration of 10-15 for 4 weeks on serum calcium and serum ALP of the mice are
shown in Figure 7. The data indicate that the serum calcium and serum ALP of 10-15 treated
mice are significantly lower than that of ovariotomy and estradiol treated mice. This means
that the frequency of bone turnover of 10-15 orally treated mice is significantly lower than that
of estradiol treated mice, the efficacy of oral 10-15 in inhibiting bone turnover is significantly
higher than that of estradiol.
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Figure 7. Serum calcium and ALP of 10-15 treated mice. Dose = 110.3 nmol/kg, n=12, a) Compared to ovariotomy
and estradiol P<0.01; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy P<0.01, to estradiol P<0.05. The
statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
3.2. Covalent modification of estradiol with RGD-octapeptides preventing bone loss
The effect of orally administration of 10-15 for 4 weeks on the bone loss of the treated mice is
shown in Figure 8, of which the activity is represented with dry femur weight and femur ash
weight. The data indicate that both the weights of dry femur and femur ash of 10-15 treated
mice are significantly higher than that of ovariotomy and estradiol treated mice. This means
that when orally dosed 10-15 effectively inhibit the mice to lose femur and their efficacy is
significantly higher than that of estradiol, and the covalent modification of estradiol benefits
the inhibition of bone loss.
Figure 8. Weight of dry femur and femur ash of conjugates 10-15 treated mice. Dose =110.3 nmol/kg, n=12; a) Com‐
pared to ovariotomy P<0.05; b) Compared to ovariotomy and estradiol P<0.01. The statistical analysis of the data was
carried out by use of an ANOVA test and p<0.05 was considered significant.
3.3. Covalent modification of estrone with RGD-octapeptides inhibiting bone turnover
Using carbonylmethyl group as the linker the 3-hydroxy of estrone was modified with RGD-
octapeptides and provided 16-18 (Figure 6). The effects of oral administration of 16-18 for 4
weeks on serum calcium and serum ALP of the mice are shown in Figure 9. The data indicate
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that the serum calcium and serum ALP of 16-18 treated mice are significantly lower than that
of ovariotomy and estrone treated mice. This means that the frequency of bone turnover of
16-18 orally treated mice is significantly lower than that of estrone treated mice, the efficacy
of oral 16-18 in inhibiting bone turnover is significantly higher than that of estrone.
Figure 9. Serum calcium and serum ALP of 16-18 treated mice. Dose = 110.3 nmol/kg, n=12, a) Compared to ovariot‐
omy P<0.01, to estrone P<0.05; b) Compared to ovariotomy P<0.05; c) Compared to ovariotomy and estrone P<0.01.
The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
3.4. Covalent modification of estrone with RGD-octapeptides preventing bone loss
The effect of orally administration of 16-18 for 4 weeks on the bone loss of the treated mice is
shown in Figure 10, their activities are represented with dry femur weight and femur ash
weight. The data indicate that both the weights of dry femur and femur ash of 16-18 treated
mice are significantly higher than that of ovariotomy and estradiol treated mice. This means
that upon oral administration 16-18 effectively inhibit the mice losing femur, their efficacies
are significantly higher than that of estrone, and the covalent modification of estrone prevents
the bone loss.
Figure 10. Weight of dry femur and femur ash of conjugates 16-18 treated mice. Dose =110.3 nmol/kg, n=12; a)
Compared to ovariotomy and estrone P<0.01; b) Compared to ovariotomy P<0.01, to estrone P<0.05. The statistical
analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
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3.5. Covalent modification of estradiol with two RGD-octapeptides inhibiting bone
turnover
Using succinyl group as the linker of the 17β-hydroxy and using carbonylmethyl group as the
linker of the 3-hydroxy estradiol was simultaneously modified with RGD-tetrapeptides and
provided 19-21 (Figure 6). The effects of oral administration of 19-21 for 4 weeks on serum
calcium and serum ALP of the mice are shown in Figure 11. The data indicate that the serum
calcium and serum ALP of 19-21 treated mice are significantly lower than that of ovariotomy
and estradiol treated mice. This means that the frequency of bone turnover of 19-21 orally
treated mice is significantly lower than that of estradiol treated mice, the efficacy of oral 19-21
in inhibiting bone turnover is significantly higher than that of estradiol.
Figure 11. Serum calcium and serum ALP of 19-21 treated mice. Dose = 110.3 nmol/kg, n=12. The statistical analysis
of the data was carried out by use of an ANOVA test and p<0.05 was considered significant. For serum calcium a)
Compared to ovariotomy P<0.05; For serum ALP b) compared to ovariotomy and estradiol P<0.01.
3.6. Covalent modification of estradiol with two RGD-octapeptides preventing bone loss
The effect of orally administration of 19-21 for 4 weeks on the bone loss of the treated mice
is shown in Figure 12, their activities are represented with dry femur weight and femur
ash weight. The data indicate that both the weights of dry femur and femur ash of 19-21
treated mice are significantly higher than that of ovariotomy and estradiol treated mice.
This means that upon oral administration 19-21  effectively inhibit the mice losing femur,
their  efficacies are significantly higher than that  of  estradiol,  and the covalent modifica‐
tion of estrone prevents the bone loss.
3.7. Covalent modification of estradiol with RGD-octapeptides inducing no endometrial
cell hyperplasia
The effect of orally administration of 10-21 for 4 weeks on the endometrial cell hyperplasia of
the mice was observed, of which the inhibition is represented with uteri weight. The data
indicate that the weight of the uteri of 10-21 treated mice is significantly lower than that of
ovariotomy and estradiol treated mice. This means that, in contrast to estradiol and estrone,
oral administration of 10-21 induces no observable endometrial cell hyperplasia, and the
covalent modification of estradiol and estrone with RGD-octapeptides limits the dose-related
adverse effects of estradiol.
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3.8. Covalent modification of estradiol with RGD-octapeptides having no thrombosis risk
The effect of orally administration of 10-21 for 4 weeks on thrombosis risk of the mice was
observed, of which the risk is represented with tail bleeding time. The data indicate that the
tail bleeding time of 10-21 treated mice is significantly longer than that of ovariotomy, estradiol
and estrone treated mice. This means that, in contrast to estradiol and estrone, oral adminis‐
tration of 10-21 induces no observable thrombosis risk, and the covalent modification of
estradiol and estrone with RGD-octapeptides limits the dose-related adverse effects of
estradiol.
3.9. Summary of covalent modification of estrogen with RGD-octapeptides
With RGD-octapeptides modifying one hydroxyl  group of  estradiol  and estrone or with
RGD-tetrapeptides simultaneously modifying two hydroxyl groups of estradiol resulted in
12 conjugates. On ovariotomy mouse model and at 110.3 nmol/kg of oral dose their anti-
osteoporosis  activities were significantly higher than that  of  estradiol  and estrone them‐
selves. In contrast to estradiol and estrone themselves, the anti-osteoporosis therapy of these
conjugates  induced no  endometrial  cell  hyperplasia  and thrombosis  risk.  Comparing  to
RGD-tetrapeptide  modified  estradiol  and estrone  the  effective  dose  of  RGD-octapeptide
modified estradiol and estrone is 1000 folds lower. This means that the anti-osteoporosis
efficacy of RGD-octapeptide modified estradiol and estrone is 1000 folds higher than that
of  RGD-tetrapeptide  modified  estradiol  and  estrone.  Reasonably,  this  dramatically  en‐
hanced efficacy could attitude to the introduction of RGD-octapeptides. Furthermore, due
to ovariotomy mouse model simulates the bone loss condition of postmenopausal women
and  high  activity  these  RGD-octapeptides  modified  estradiol  and  estrone  should  be
preferentially promising candidates for HRT use.
Figure 12. Weight of dry femur and femur ash of conjugates 19-21 treated mice. Dose =110.3 nmol/kg, n=12,
weights of dry femurs and femur ashes are represented as X±SD mg; a) Compared to ovariotomy, estradiol P<0.01; b)
Compared to ovariotomy P<0.01, to estradiol P<0.05.
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4. Direct covalent modification of androgen with RGD-tetrapeptides
In the improvements of the efficacy of HRT, the anti-osteoporosis efficacy of androgen is found
to be higher than that of estrogen, inducing no endometrial cell hyperplasia and having no
thrombosis risk. Particularly in the research of androgen, 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one is disclosed as a new androgen. Comparing to estrone and estrogen 17β-ami‐
no-11α-hydroxyandrost-1,4-diene-3-one has higher anti-osteoporosis activity and raises no
endometrial cell hyperplasia and thrombosis risk. Thus 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one is selected as the androgen and directly and covalently modified with RGD-
tetrapeptides (22-24, Figure 13) [32].
Figure 13. Structures of conjugates of androgen and RGD-tetrapeptides. In 22 AA = Ser, in 23 AA = Val, in 24 AA =
Phe.
4.1. Direct covalent modification of androgen with RGD-tetrapeptides inhibiting bone
turnover
The direct covalent modification of the 17β-amino of 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one (androgen) with RGD-tetrapeptides provided 22-24 (Figure 13). The effect of oral
administration of 22-24 plus intramuscular prednisone for 4 weeks on serum calcium and
serum ALP of the mice is shown in Figure 14. The data indicate that the serum calcium and
serum ALP of oral administration of 22-24 plus intramuscular prednisone treated mice are
significantly lower than that of prednisone alone and oral administration of estradiol plus
intramuscular prednisone treated mice. This means that the frequency of bone turnover of
22-24 orally treated mice is significantly lower than that of androgen treated mice, the efficacy
of oral 22-24 in inhibiting bone turnover is significantly higher than that of estradiol.
4.2. Direct covalent modification of androgen with RGD-tetrapeptides preventing bone loss
The effect of oral administration of 22-24 plus intramuscular prednisone for 4 weeks on the
bone loss of the treated mice is shown in Figure 15, their activities are represented with dry
femur weight and femur ash weight. The data indicate that both the weights of dry femur and
femur ash of oral adminis-tration of 22-24 plus intramuscular prednisone treated mice are
significantly higher than that of intramuscular prednisone alone and oral administration of
estradiol plus intramuscular prednisone treated mice. This means that upon oral administra‐
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tion 22-24 effectively inhibit the mice losing femur, their efficacies are significantly higher than
that of estradiol, and the direct covalent modification of androgen prevents the bone loss.
Figure 15. Weight of dry femur and femur ash of conjugates 22-24 treated mice. ip Dose of prednisone (PDN): 6.3
mg/kg, twice a week; oral dose of 22-24: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a
day; n = 12. a) Compared to NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND and E2 + PND p< 0.05. The
statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
4.3. Direct covalent modification of androgen with RGD-tetrapeptides increasing total
vBMD
CT measured 3D bone geometry and the size-independent vBMD, as well as pQCT quantita‐
tively measured 3D bone geometry and size-independent vBMD were used to represent the
anti-osteoporosis efficacy of 22-24 and are shown in Figure 16. The data indicates that the total
vBMD of the femurs of NS plus intramuscular prednisone treated mice is significantly lower
than that of the femurs of NS alone treated mice. This means that intramuscular administration
of prednisone effectively induces the mice to decrease the total vBMD. The total vBMDs of the
Figure 14. Serum calcium and ALP of 22-24 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg, twice a week; oral
dose of 22-24: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a day; n = 12. a) Compared to
NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND p< 0.01, to E2 + PND p< 0.05; c) Compared to NS + PND p<
0.05; d) Compared to NS + PND and E2 + PND p< 0.01. The statistical analysis of the data was carried out by use of an
ANOVA test and p<0.05 was considered significant.
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femurs of oral administration of 22-24 plus intramuscular prednisone treated mice are
significantly higher than that of the femurs of NS plus intramuscular prednisone treated mice.
This means that upon oral administration 22-24 effectively prevent intramuscular adminis‐
tration of prednisone treated mice decreasing total vBMD.
4.4. Direct covalent modification of androgen with RGD-tetrapeptides increasing trabecular
vBMD
Figure 17 indicates that the trabecular vBMD of the femurs of NS plus intramuscular admin‐
istration of prednisone treated mice is significantly lower than that of the femurs of NS alone
treated mice. This means that prednisone effectively induces the mice to decrease trabecular
vBMD. The trabecular vBMDs of the femurs of oral administration of 22-24 plus intramuscular
administration of prednisone treated mice are significantly higher than those of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 22-24 effectively prevent intra-muscular administration of prednisone treated
mice decreasing trabecular vBMD.
4.5. Direct covalent modification of androgen with RGD-tetrapeptides inducing no
endomtrial cell hyperplasia
The effect of oral administration of 22-24 plus intramuscular administration of prednisone for
4 weeks on the endometrial cell hyperplasia of the mice was observed, and their inhibition
activities are represented with uteri weight. The data indicate that the weight of the uteri of
oral administration of 22-24 plus intramuscular administration of prednisone treated mice is
significantly lower than that of intramuscular administration of prednisone alone and oral
administration of estradiol plus intramuscular administration of prednisone treated mice. This
means that, in contrast to oral administration of estradiol, oral administration of 19-21 induces
no observable endometrial cell hyperplasia, and the direct covalent modification of androgen
with RGD-tetrapeptides induces no dose-related adverse effects of estradiol.
Figure 16. Total vBMD and images of pQCT scanning at a distance from the proximal femur growth palate corre‐
sponding to < 6 % of the total length of the femur of 22-24 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg,
twice a week; oral dose of 22-24: 110 nmol/kg, once a day; n = 12. a) Compared to NS alone , NS + PND, 23 + PDN and
22 + PDN p< 0.01; b) Compared to NS alone , NS + PND and 22 + PDN c) Compared to NS alone and NS + PND p< 0.01.
The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
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4.6. Direct covalent modification of androgen with RGD-tetrapeptides having no
thrombosis risk
The effect of oral administration of 22-24 plus intramuscular administration of prednisone for
4 weeks on thrombosis risk of the mice was observed, and the risk is represented with tail
bleeding time. The data indicate that the tail bleeding time of oral administration of 22-24 plus
intramuscular administration of prednisone treated mice is significantly longer than that of
ntramuscular administration of prednisone alone and oral administration of estradiol plus
intramuscular administration of prednisone treated mice. This means that, in contrast to oral
administration of estradiol, oral administration of 22-24 induces no observable thrombosis risk,
and the direct covalent modification of androgen with RGD-tetrapeptides induces no dose-
related adverse effects of estradiol.
4.7. Summary of direct covalent modification of androgen with RGD-tetrapeptides
RGD-octapeptides directly modifying the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one  was  performed  by  amidation  and  resulted  in  3  conjugates.  On
prednisone treated mouse model and at 110 nmol/kg of oral dose their anti-osteoporosis
activities were significantly higher than that of estradiol. In contrast to estradiol, the anti-
osteoporosis  therapy  of  these  conjugates  induced  no  endometrial  cell  hyperplasia  and
thrombosis risk. Comparing to RGD-tetrapeptide modified estradiol the effective dose of
RGD-octapeptide  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  is  1000  folds
lower.  This  means  that  the  anti-osteoporosis  efficacy  of  RGD-octapeptide  modified 17β-
amino-11α-hydroxyandrost-1,4-diene-3-one is 1000 folds higher than that of RGD-tetrapep‐
tide modified estradiol. Reasonably, this dramatically enhanced efficacy could attitude to
the introduction of 17β-amino-11α-hydroxyandrost-1,4-diene-3-one. In addition to premeno‐
pausal women and in older men, secondary osteoporosis is common in the patients treated
with glucocorticoids and in prostate cancer patients receiving androgen deprivation therapy
(ADT) in particular. Glucocorticoids are ubiquitously prescribed in the fields of rheumatol‐
Figure 17. Trabecular vBMD of the femurs of the treated mice at a distance from the proximal femur growth palate
corresponding with < 6 % of the total length of the femurs of 22-24 treated mice. a) Trabecular vBMD is represented
with mean ± SD mg/cm3, n = 12, PDN = prednisone, dose = 110 nmol/kg. b) Compared to NS + PDN, 22 + PDN and 23
+ PDN p< 0.01; c) Compared to NS + PDN and 22 + PDN p< 0.01; d) Compared to NS + PDN p< 0.01.
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ogy,  respirology,  neurology,  hematology,  dermatology,  gastroenterology,  and  transplant
medicine.  Chronic exposure to pharmacological  doses of  glucocorticoids causes multiple
deleterious effects on osteopenia, osteoporosis and bone fracture. Prostate cancer is one of
the most common diseases in the older men. After the surgery or radiation therapy the
male patients with localized or metastatic prostate cancer are generally given ADT. Though
male  patients  on  ADT  usually  have  good  prognosis,  osteoporosis  is  a  very  common
consequence of this therapy and up to 20% of the patients will fracture within 5 years. To
prevent osteoporotic fracture in the female patients treated with glucocorticoids and the
male patients receiving ADT novel effective agents are needed. The ability of these RGD-
octapeptides  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  to  prevent  predni‐
sone  treated  mouse  developing  osteoporosis  suggests  that  these  conjugates  should  be
promising candidates of secondary osteoporosis therapies.
5. Indirect covalent modification of androgen with RGD-tetrapeptides
For androgen a parallel covalent modification with the direct covalent modification is an
indirect strategy. In brief, between the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one and RGD-tetrapeptides as a linker, succinyl group, is inserted to provide
RGD-tetrapeptides indirectly modified androgen (Figure 18) [33].
Figure 18. Structures of conjugates of androgen, succinyl group and RGD-tetrapeptides. In 25 AA = Ser, in 26 AA =
Val, in 27 AA = Phe.
5.1. Indirect covalent modification of androgen with RGD-tetrapeptides inhibiting bone
turnover
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on serum calcium and serum ALP of the mice is shown in Figure 19. The data indicate
that the serum calcium and serum ALP of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly lower than those of intramuscular
administration of prednisone alone and oral administration of estradiol plus intramuscular
administration of prednisone treated mice. This means that the frequency of bone turnover of
oral administration of 25-27 treated mice is significantly lower than that of oral administration
of estradiol treated mice, the efficacy of oral administration of 25-27 in inhibiting bone turnover
is significantly higher than that of oral administration of estradiol.
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Figure 19. Serum calcium and ALP of 25-27 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg, twice a week; oral
dose of 25-27: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a day; n = 12. For serum Ca+2:
a) Compared to NS + PND p< 0.01, to E2 + PND p< 0.05; b) Compared to NS + PND p< 0.05. For serum ALP: a) Com‐
pared to NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND p< 0.05.
5.2. Indirect covalent modification of androgen with RGD-tetrapeptides preventing bone loss
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on the bone loss of the treated mice is shown in Figure 20, their activities are repre‐
sented with dry femur weight and femur ash weight. The data indicate that both the weights
of dry femur and femur ash of oral administration of 25-27 plus intramuscular administration
of prednisone treated mice are significantly higher than those of intramuscular administration
of prednisone alone and oral administration of estradiol plus intramuscular administration of
prednisone treated mice. This means that upon oral administration 25-27 effectively inhibit
the mice to losing femur, their efficacies are significantly higher than that of oral administration
of estradiol, and the direct covalent modification of androgen prevents the bone loss.
Figure 20. Weight of dry femur and femur ash of conjugates 25-27 treated mice. ip Dose of prednisone (PDN): 6.3
mg/kg, twice a week; oral dose of 25-27: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a
day; n = 12. For dry femur: a) Compared to NS + PND and E2 + PND p< 0.05; b) Compared to NS + PND and E2 + PND
p< 0.05. For femur ash: a) Compared to NS + PND and E2 + PND p< 0.01.
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5.3. Indirect covalent modification of androgen with RGD-tetrapeptides increasing total
vBMD
CT measured 3D bone geometry and the size-independent vBMD, as well as pQCT quantita‐
tively measured 3D bone geometry and size-independent vBMD were used to represent the
anti-osteoporosis efficacy of 25-27 and are shown in Figure 21. The data indicates that the total
vBMD of the femurs of NS plus intramuscular administration of prednisone treated mice is
significantly lower than that of the femurs of NS alone treated mice. This means that intra‐
muscular administration of prednisone effectively induces the mice to decrease the total
vBMD. The total vBMDs of the femurs of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly higher than that of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 25-27 effectively inhibit intramuscular administration of prednisone treated
mice decreasing total vBMD.
Figure 21. Total vBMD and images of pQCT scanning at a distance from the proximal femur growth palate corre‐
sponding to < 6 % of the total length of the femur of 25-27 treated mice.
5.4. Indirect covalent modification of androgen with RGD-tetrapeptides increasing
trabecular vBMD
Figure 22 indicates that the trabecular vBMD of the femurs of NS plus intramuscular admin‐
istration of prednisone treated mice is significantly lower than that of the femurs of NS alone
treated mice. This means that prednisone effectively induces the mice to decrease trabecular
vBMD. The trabecular vBMDs of the femurs of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly higher than that of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 25-27 effectively inhibit intramuscular administration of prednisone treated
mice decreasing trabecular vBMD.
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Figure 22. Trabecular vBMD in the femurs of treated mice at a distance from the proximal femur. Growth plate corre‐
sponds with < 6% of the total length of the femur of the treated mice. Trabecular vBMD is represented with mean ±
SD mg/cm3, n = 12, PDN = prednisone, dose of 25-27 = 110 nmol/kg. a) Compared to NS + PDN, 25 + PDN and 26 +
PDN p< 0.01; b) Compared to NS + PDN and 27 + PDN p< 0.01; c) Compared to NS + PDN p< 0.01.
5.5. Indirect covalent modification of androgen with RGD-tetrapeptides inducing no
endomtrial cell hyperplasia
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on the endometrial cell hyperplasia of the mice was observed, and their inhibition
activities are represented with uteri weight. The data indicate that the weight of the uteri of
oral administration of 25-27 plus intramuscular administration of prednisone treated mice is
significantly lower than that of intramuscular administration of prednisone alone and oral
administration of estradiol plus intramuscular administration of prednisone treated mice. This
means that, in contrast to oral administration of estradiol, upon oral administration 25-27
induces no observable endometrial cell hyperplasia, and the direct covalent modification of
androgen with RGD-octapeptides induces no dose-related adverse effects of estradiol.
5.6. Indirect covalent modification of androgen with RGD-tetrapeptides having no
thrombosis risk
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on thrombosis risk of the mice was observed, and the risk is represented with tail
bleeding time. The data indicate that the tail bleeding time of oral administration of 25-27 plus
intramuscular administration of prednisone treated mice is significantly longer than that of
ntramuscular administration of prednisone alone and oral administration of estradiol plus
intramuscular administration of prednisone treated mice. This means that, in contrast to oral
administration of estradiol, upon oral administration 25-27 induces no observable thrombosis
risk, and the indirect covalent modification of androgen with RGD-octapeptides induces no
dose-related adverse effects of estradiol.
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5.7. Summary of indirect covalent modification of androgen with RGD-tetrapeptides
RGD-tetrapeptides indirectly modifying the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one was performed by inserting a succinyl functional group and result‐
ed in 3 conjugates. On prednisone treated mouse model and at 110 nmol/kg of oral dose
their  anti-osteoporosis  activities  were  significantly  higher  than that  of  estradiol.  In  con‐
trast to estradiol, the anti-osteoporosis therapy of these conjugates induced no endometri‐
al cell hyperplasia and thrombosis risk. In respect to inhibiting the prednisone treated mice
to  lose  total  vBMD,  trabecular  vBMD,  femur  ash  weight,  femur  Ca2+  and bone  mineral
content 110 nmol/kg of RGD-tetrapeptides indirectly modified 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one was more effective than 110 nmol/kg of RGD-tetrapeptides directly
modified 17β-amino-11α-hydroxyandrost-1,4-diene-3-one, and this increased efficacy could
be  attributed  to  the  insertion  of  a  succinyl  group.  Similarly,  the  ability  of  these  RGD-
octapeptides  indirectly  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  to  pre‐
vent  prednisone  treated  mouse  developing  osteoporosis  and high  activity  suggests  that
these conjugates should be preferentially promising candidates for secondary osteoporo‐
sis therapies.
6. Nano-structures of RGD-peptides modified estrogen and androgen
Self-organization or self-assembly practically leads to the formation of various ordered
nanostructures in solution, at bulk state, and on a solid surface [34,35]. Numerous self-
assembling substances, such as highly fluorinated amphiphilic molecules[36], amphiphilic
triblock copolymers with polyrotaxane as a central block [37], amphiphilic dodecyl ester
derivatives from aromatic amino acids [38], dendritic molecules [39], the shape anisotropy of
non-spherical colloidal building blocks [40], alkylated polycyclic aromatic hydrocarbons [41],
porphyrins, graphenes and fullerenes [42], were designed. Of the self-assembling molecules,
peptides have been considered a set of particular substance [43-51]. In respect of the self-
assembly the formation of nano-structure is an inherent property of organic compounds. In
this context, the nano-structures of 10-15 and 22-27 in aqueous are given below to explore the
relationships between the nano-structure and the concentration or pH, as well as to correlate
the nano-feature with the pharmacological activity.
6.1. Nano-aggregators from modification of 17β-hydroxy of estradiol with RGD-
octapeptides
As explained by Figure 6, using succinyl group and RGD-octapeptides modifying the 17β-
hydroxy of estradiol provides 10-12. Figure 23 demonstrates that in water 10 forms stick like
nano-aggregators of 161.1 nm in diameter and 222.2-888.9 nm in length, 11 forms maize like
nano-aggregator of 388.9 nm in length, 12 forms solid pipe like nano-aggregator of 3.6 nm in
diameter and 263.9 nm in length.
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Figure 23. TEM images of 10 - 12 formed nano-aggregators. A) Stick like nano-aggregators of 10; B) Maize like nano-
aggregators of 11; C) Solid pipe like nano-aggregator of 12.
6.2. Nano-aggregators from modification of 3-hydroxy of estradiol with RGD-
octapeptides
As seen in Figure 6, carbonylmethyl and RGD-octapeptides modifying the 3-hydroxy of
estradiol provides 13-15. Figure 24 demonstrates that in water 13 forms porous nano-aggre‐
gators of 133.3-430.6 nm in length, 14 forms maize like nano-aggregator of 111.1-600.0 nm in
length, 15 forms nano-globes of 66.7-237.5 nm in diameter.
Figure 24. TEM images of 13 - 15 formed nano-aggregators. A) Porous nano-aggregators of 13; B) Porous nano-ag‐
gregators of 14; C) Nano-globes of 15.
6.3. TEM image of nano-globes of androgen having RGD-tetrapeptides modified 17β-
hydroxy
The nano-structures of 22-24 were explained with TEM nano-images and are shown with
Figures  25-27.  Figure  26  indicates  that  in  1.1  mM aqueous solution 22  forms numerous
smaller globes aggregated nano-globe of 400 nm in diameter, dispersing globes of 55 - 200
nm in diameter, and dispersing globes of 18 - 146 nm in diameter. Figure 41 indicates that
in 1.1 mM aqueous solution  23  forms nano-globe of  312.5 nm in diameter having small
globes, blocks and awls on surface, nano-globes of 21.9 - 82.9 nm in diameter and nano-
globes of 22.9 -  194.3 nm in diameter.  Figure 27 indicates that in 1.1 mM aqueous solu‐
tion 24  forms nano-globe of  183  nm in  diameter  having a  number  of  nano-particles  on
surface,  hemisphere  of  275  nm  in  diameter  having  some  smaller  globes  on  incomplete
surface and nano-globes of 48 - 188 nm in diameter.
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Figure 25. TEM images of 1.1 mM of 22 in ultrapure water. A) Numerous smaller globes aggregated nano-globe of
400 nm in diameter; B) Dispersing globes of 55 - 200 nm in diameter; C) Dispersing globes of 18 - 146 nm in diameter.
Figure 26. TEM images of 1.1 mM of 23 in ultrapure water. A) Nano-globe of 312.5 nm in diameter having small
globes, blocks and awls on surface; B) Nano-globes of 21.9 - 82.9 nm in diameter; C) Nano-globes of 22.9 - 194.3 nm
in diameter.
Figure 27. TEM images of 1.1 mM of 24 in ultrapure water. A) Nano-globe of 183 nm in diameter having a number of
nano-particles on surface; B) A hemisphere of 275 nm in diameter having some smaller globes on incomplete surface;
C) Nano-globes of 48 - 188 nm in diameter.
6.4. SEM image of nano-globes of androgen having RGD-tetrapeptides modified 17β-
hydroxy
The nano-structures of 22-24 were explained with SEM nano-images and are shown with
Figures 28-30. Figure 29 indicates that in solid state 22 exists as globes of 3.3 - 14.2 μm in
diameter. Figure 44 indicates that in solid state 23 exists as eggs of 9.6 × 11.5 μm to 19.5 × 27.0
μm in diameter, of which surfaces have small eggs, and one egg remains its tail been incom‐
plete. Figure 30 indicates that in solid state 24 exists as beads of 9.2 × 10.0 μm to 21.4 × 22.8 μm
in diameter, and beads remain been incomplete.
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Figure 28. SEM images of 22 in solid state. A) Globes of 3.3 - 6.6 µm in diameter; B) Globes of 3.3 - 14.2 µm in diame‐
ter; C) Globes of 3.3 - 11.7 µm in diameter.
Figure 29. SEM images of 23 in solid state. A) Egg of 12.9 × 14.4 µm in diameter; B) Egg of 19.5 × 27.0 µm in diame‐
ter; C) Egg of 9.6 × 11.5 µm in diameter and egg remains its tail been incomplete.
Figure 30. SEM images of 24 in solid state. A) Bead of 9.2 × 10.0 µm in diameters, and bead remains been incomplete;
B) Hollow bead of 21.4 × 22.8 µm in diameters; C) Bead of 12.6 × 21.1 µm in diameter, and bead of 15.3 × 22.1 µm in
diameter.
6.5. TEM image of nano-globes of androgen having RGD-tetrapeptides and succinyl
modified 17β-hydroxy
The TEM images (Figures 31-33) demonstrate that in water 25-27 consistently form nano-
globes with porous surface. The comparison of the nano-globes of 22-24 having no porous
surface and the nano-globes of 25-27 having porous surface gave us an impression that the
insertion of succinyl was a key to form the nano-globes with porous surface, 17β-ethyl-car‐
bonylaminoandrost-1,4-diene-3-one was responsible for forming nano-globe, and RGD-tet‐
rapeptide was responsible for characterizing the surface feature and size of the nano-globes,
in particular. For instance, RGDS causes 25 to form dispersing nano-globes of 8 - 150 nm in
diameter and having porous surfaces, RGDV causes 26 to form dispersing nano-globes of 29
- 150 nm in diameter and having porous surfaces, and RGDF causes 27 to form dispersing
nano-globes of 76 - 343 nm in diameter and having porous surfaces.
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Figure 31. TEM images of 1.1 μM of 25 in ultrapure water. A) Dispersing globes of 8 - 150 nm in diameter; B) Dispers‐
ing globes of 17 - 94 nm in diameter; C) Dispersing globes of 27 - 82 nm in diameters.
Figure 32. TEM images of 1.1 μM of 26 in ultrapure water. A)Dispersing globes of 29 - 69 nm in diameter; B) Dispers‐
ing globes of 70 - 120 nm in diameter; C) Dispersing globes of 67 - 150 nm in diameter.
Figure 33. TEM images of 1.1 μM of 27 in ultrapure water. A) Dispersing globes of 320 - 343 nm in diameter; B) Dis‐
persing globes of 76 - 139 nm in diameter; C) Dispersing globes of 120 - 171 nm in diameter.
6.6. SEM image of nano-globes of androgen having RGD-tetrapeptides and succinyl
modified 17β-hydroxy
The SEM image (Figures 34-36) demonstrates that in solid state 25-27 exist as nano-globes of
15 nm - 6.4 μm in diameter, nano-pine seeds of 286 nm - 2.7 μm in length, nano-eggs of 1.3 -
12.9 μm in length, nano-pinecones of 5.0 - 5.6 μm in length, nano-gear of 10 μm in diameter,
nano-calabash of 4 μm in length, and uncompleted nano-calabash of 11.3 μm in length. The
coexistence of nano-globe having nano-egg, nano-pine seed having nano-pinecone, and
uncompleted nano-calabash having nano-calabash implies that the nano-egg, nano-pinecone
and nano-calabash are built by nano-globes, nano-pine seeds and uncompleted nano-calabash.
The correlation of the molecular constitutions and the nano-structures gave us an impression
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that for 25 - 27 17β-ethylcarbonyl-amino-androst-1,4-diene-3-one was responsible for forming
a globe-like body, and RGD-tetrapeptide was responsible for characterizing globe-like body.
Figure 34. SEM images of 25 in solid state. A) Nano-globes of 15 nm - 2 µm in diameter and nano-calabash of 4 µm in
length; B) Nano-globes of 600 nm - 1.3 µm in diameter and nano-egg of 1.3 µm in length; C) Nano-globes of 3.0 - 5.0
µm in diameter and uncompleted nano-calabash of 11.3 µm in length.
Figure 35. SEM images of 26 in solid state. A) Globe of 2.9 µm in diameter; B) Globes of 5.0 - 6.4 µm in diameter and
eggs of 5.7 - 12.9 µm in length; C) Globes of 2.8 - 3.5 µm in diameter.
Figure 36. SEM images of 27 in solid state. A) Pine seeds of 7.1 - 9.4 µm in length; B) Globe of 8.1 µm in diameter; C)
Gear of 10 µm in diameter.
6.7. Summary of the nano-structures of RGD-peptides modified sex hormones
In water RGD-peptides modified sex hormones generally formed diverse nano-species via self-
assembly. Due to all non-covalent bond interactions could be involved into the self-assembly
the size and the feature of the nano-species of RGD-peptides modified sex hormones clearly
depend on the concentration of their aqueous solution. Similarly, due to all non-covalent bond
interactions could be involved into the self-assembly the size and the feature of the nano-
species usually depend on the chemical structures of the sex hormones and the sequence of
the RGD-peptides. In addition, the RGD-peptides modified sex hormones possessed various
anti-osteoporosis activities. Thus the feature and the size of their nano-species could be
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correlated with their anti-osteoporosis activities. Therefore by selecting the concentration and
by modifying the chemical structure we are able to optionally get the desirable nano-structure
and consequently to optionally get desirable anti-osteoporosis activity.
7. Conclusions
Secondary osteoporosis is common in premenopausal women with osteoporosis and in older
men, and is a major problem in clinical practice. More than one third of women with postme‐
nopausal osteoporosis have identifiable secondary causes that contribute to bone loss. The
secondary causes of osteoporosis in older men account for 50% - 80% of the cases of bone loss
leading to fracture. Besides, secondary osteoporosis is common in the patients treated with
glucocorticoids and in prostate cancer patients receiving ADT in particular. Glucocorticoids
are ubiquitously prescribed in the fields of rheumatology, respirology, neurology, hematology,
dermatology, gastroenterology, and transplant medicine. Chronic exposure to pharmacolog‐
ical doses of glucocorticoids causes multiple deleterious effects on osteopenia, osteoporosis
and bone fracture. Prostate cancer is one of the most common diseases in the older men. After
the surgery or radiation therapy the male patients with localized or metastatic prostate cancer
are generally given ADT. Though male patients on ADT usually have good prognosis,
osteoporosis is a very common consequence of this therapy and up to 20% of the patients will
fracture within 5 years. To prevent osteoporotic fracture in premenopausal women with
osteoporosis, the female patients treated with glucocorticoids and the male patients receiving
ADT RGD-peptides modified sex hormones were provided. On ovariotomy and prednisone
induced osteoporosis mice either ip injection or orally dosed the modified hormones were able
to enhance the efficacy and minimize the adverse effects. By forming nano-species their
therapy could be further improved.
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